A recent study described series of TYR‐targeting molecules based on oxazole and diazole scaffolds, yielding for examples compounds 79 and 80, which are low nanomolar mTYR inhibitors (IC50=0.006–0.011 μM when using l‐tyrosine as substrate).[152] These compounds were evaluated as potential neuromelanogenesis suppressors, with possible applications in the treatment of Parkinson's disease (PD). Here, TYR is linked to Parkinson disease.